生物基因公司
(BIIB)

  • 股價
    219.21
  • 漲跌
    0.13
  • 漲幅
    0.06%
  • 成交量
    8.9萬
YahooFinanceBusiness
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2023 Earnings Call Transcript February 14, 2024
Sage Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Operator: Good morning. Welcome to SAGE Therapeutics' Fourth Quarter a
    YahooFinanceBusiness
    Shareholders might have noticed that Biogen Inc. (NASDAQ:BIIB) filed its full-year result this time last week. The early response was not positive, with shares down 8.2% to US$221 in the past week. Statutory earnings per share fell badly short of expectations, coming in at US$7.97, some 21% below a
      YahooFinanceBusiness
      Tuesday, Biogen Inc (NASDAQ:BIIB) posted fourth-quarter 2023 sales of $2.39 billion, missing the consensus of $2.46 billion, down 6% Y/Y and 5% at constant currency (CC).
      Adjusted EPS of $2.95, down 27%, missing the consensus of $3.18.
      Biogen’s partner, Eisai Co Ltd (OTC:ESALY), has faced a delay
        YahooFinanceBusiness
        Biogen Inc. (NASDAQ:BIIB) Q4 2023 Earnings Call Transcript February 13, 2024
        Biogen Inc. beats earnings expectations. Reported EPS is $3.3, expectations were $3.16. Biogen Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
        Operat
          美股周二 (13 日) 暴跌,道瓊指數出現 2023 年 3 月以來的最大單日跌幅,主要原因是美國公債殖利率飆升,此前通膨報告超出預期,讓聯準會更快、更激進降息周期的預期降溫。
            YahooFinanceBusiness
            Biogen (NASDAQ: BIIB)Q4 2023 Earnings CallFeb 13, 2024, 8:00 a.m. ET
            Prepared Remarks
            Questions and Answers
            Call Participants
            
            Operator
            Good morning. My name is Katie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen fourth quarter and
              YahooFinanceBusiness
              On the last day of 2023, PRIMECAP Management (Trades, Portfolio) made a notable addition to its investment portfolio by acquiring additional shares in Biomarin Pharmaceutical Inc (NASDAQ:BMRN). The transaction, dated December 31, 2023, saw the firm adding 7,835 shares at a trade price of $96.42. Th